Liquid biopsies and novel non-invasive diagnostics
In the past, diagnosing disease often meant invasive procedures, long waits, and limited insights. Today, liquid biopsies (blood-based tests that analyze circulating biomarkers such as tumor DNA fragments, RNA, and proteins) are changing that story. With a simple blood draw, these tests provide a powerful, non-invasive window into cancer, genetic disorders, and early signs of disease. Combined with advanced analytics like AI-driven algorithms and next-generation sequencing, liquid biopsies are making precision medicine, including personalized treatment and monitoring, faster, safer, and more accessible than ever before. This Accelerating Science Feature page explores how liquid biopsies are transforming how clinicians track health and fight illness.
Liquid biopsies for early cancer detection
This Accelerating Science Forum explores the future of early cancer detection and the science behind better liquid biopsies.
Watch the roundtable discussion on demand to:
- Gain insights into cutting-edge advancements in multicancer early detection assay development, including strategies for improving sensitivity and specificity.
- Understand best practices for assay distribution, with a focus on ensuring accessibility and minimizing logistical challenges.
- Learn pre-analytical techniques to streamline workflows and maximize scalability in multicancer early detection testing.
- Acquire knowledge on how to collaborate effectively with key opinion leaders to drive innovation and optimize implementation of MCED assays.
Reserve your free space to gain insights from liquid biopsy experts at GRAIL, Biodesix, and Streck.
Dr. Lauren Murphy at the Weatherall Institute of Molecular Medicine (WIMM) at University of Oxford is investigating how platelets could hold the key to detecting cancer in patients with minimal residual disease. Discover how her research suggests that analyzing platelet DNA alongside plasma could extend the detection window and improve relapse monitoring, opening new possibilities for earlier and more precise interventions.
Read article
In this on-demand rountable discussion, leaders from the clinical and research community share their experiences navigating the evolving landscape of molecular diagnostics. This session explores how molecular diagnostics is driving real-world impact, how labs at the forefront of innovation are adapting to new pressures, and how thoughtful implementation of innovation can yield both scientific and operational rewards.
Register for free
DNA-free nucleic acid isolation kits streamline molecular diagnostics, improving sensitivity, speed, and automation for early diagnosis and monitoring.
Read article
New automations in liquid biopsy research are key to fully realizing the clinical utility in monitoring cancer, from diagnosis through to remission.
Read article
See how automation enhances efficiency, accuracy, and reproducibility in the diagnostic processes that are crucial for next-gen treatment and improved patient outcomes.
Read article